Evidence map›Paper›PMID 38803181›Full record

ArticleCombinatorial chemistry & high throughput screening2025

Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis.

Cuijuan Zhao, Guixian Ji, Xingliang Zhao, Tengqi Ma, Yanhua Li, Wenbo Wu, Lu Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cuijuan ZhaoDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Guixian JiDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xingliang ZhaoDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Tengqi MaDepartment of Gastroenterology, Third Affiliated Hospital of Inner Mongonia Medical University (Inner Mongolia Baogang Hospital), Baotou, 014010, China.
Yanhua LiDepartment of Gastroenterology, Third Affiliated Hospital of Inner Mongonia Medical University (Inner Mongolia Baogang Hospital), Baotou, 014010, China.
Wenbo WuDepartment of Gastroenterology, Third Affiliated Hospital of Inner Mongonia Medical University (Inner Mongolia Baogang Hospital), Baotou, 014010, China.
Lu ZhouDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, 300052, China.

Funding

Inner Mongolia Autonomous Region Science and Technology Plan Project 2022YFSH0042Science Foundation of AMHT 2023YK22
6 · The paper itself

Abstract

aimsThe aim of this study was to reveal the hepatic cell landscape and function in the progression of NAFLD to NASH.

backgroundNon-Alcoholic Steatohepatitis (NASH) is the progressive form and turning point of Non-Alcoholic Fatty Liver Disease (NAFLD), which severely causes irreversible cirrhosis as well as hepatocellular carcinoma. The mechanism underlying the progression of NAFLD to NASH has not been revealed. Unraveling the mechanism of action of NAFLD-NASH is an important goal in improving the survival of patients with liver disease.

objectiveThe aim of this study is to discover heterogeneous hepatic cells during the progression of NAFLD to NASH.

methodsSingle-nucleus RNA-seq (snRNA-seq) data containing NASH in NAFLD samples were obtained from the Gene Expression Omnibus (GEO) database. Cell types in liver tissues from NASH and NAFLD were identified after dimensionality reduction analysis, cluster analysis, and cell annotation. The cell pathways in which differences existed were identified by analyzing metabolic pathways in Hepatic cells. We also identified cell subpopulations in Hepatic cells. The developmental trajectories of Hepatic cells were characterized by pseudotime trajectory analysis. Single-cell regulatory network inference and clustering analysis identified key transcription factors and gene regulatory networks in Hepatic cells. Moreover, cell communication analysis determined the potential interactions between Hepatic cells and immune cells, and heapatic stellate cells.

resultsSeven cell types were identified in NAFLD and NASH. The proportion of Hepatic cells was lower in NASH and showed greater energy metabolism and glucose metabolism activity. Hepatic cells exhibited heterogeneity, showing two cell subpopulations, Hepatic cells 1 and Hepatic cells 2. Dysregulation of lipid metabolism in Hepatic Cell 2 resulted in lipid accumulation in the liver, which might be involved in the progression of NAFLD. Four key transcription factors, BHLHE40, NFEL2L, RUNX1, and INF4A, were primarily found in Hepatic cells 2. The transcription factors within the hepatic cells 2 subpopulation mainly regulated genes related to lipid metabolism, energy metabolism, and inflammatory response. The cell communication analysis showed that hepatocyte interactions with immune cells were associated with inflammatory responses, while interactions with hepatic astrocytes were associated with liver injury and hepatocyte fibrosis.

conclusionThe hepatic cells 2 might promote the progression of NAFLD to NASH by regulating metabolic activity, which might contribute to liver injury through inflammation.

Indexed as

HepatocytesNon-alcoholic Fatty Liver DiseaseSingle-Cell AnalysisDisease ProgressionGene Regulatory NetworksHumanscell communicationcellular heterogeneity.Hepatic cellsNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitissnRNA-seq

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.